In 2020, 1.4 million men were newly diagnosed with prostate cancer. Northern and Western Europe, the Caribbean, Australia/ New Zealand, North and South America, and Southern Africa have the highest age-standardized incidence rates [1]. This is why new, innovative approaches are required, which could treat prostate cancer more efficiently and with fewer adverse effects.
Immunotherapy is one of the advancements in the treatment of the disease that has reported impressive outcomes in different stages of prostate tumors. Although traditionally believed to be useful in advanced tumors only, recent clinical evidence shows that it can be used for early-stage prostate cancer, in some cases, even as an alternative treatment option. Immunotherapy is also helpful in cases where other treatments are not effective and are no longer capable of preventing the development of prostate tumors. There are various forms of immunotherapy in modern treatment regimens, and the German medical oncologists will determine which is the most appropriate for a specific patient.
Role of Immunotherapy in Prostate Cancer Treatment
Prostate cancer immunotherapy is the latest chapter in oncological care that carries an important role in tumor management. Immunotherapy for the treatment of prostate cancer is being more often included in treatment plans, particularly in advanced or metastatic disease.
Modern immunotherapy for the treatment of prostate cancer uses a wide range of immune response mechanisms to target malignant cells [2]. It has shown promising results in patients with aggressive cancers with a rapid rise in PSA levels. Some of the immunotherapy prostate cancer types have produced deep and long-term remissions in malignancies with otherwise limited treatment options.
Immunotherapy treatment for prostate cancer can be used as a standalone option in early stages, before or after the surgery, to target microscopic leftover cancer cells. Additionally, certain immunotherapies for prostate cancer have achieved deep and lasting remissions in malignancies that typically have few treatment options, especially those with high genetic instability.
That is why today, immunotherapy for prostate cancer treatment is becoming an essential part of tumor management, even in cases previously considered not responsive. With each year, the successful use of prostate cancer treatment, immunotherapy, gives patients an opportunity for long-term tumor control and a better quality of life.
Types of Immunotherapy for Prostate Cancer
Doctors in clinics in Germany use four types of immunotherapy, each with unique advantages, mechanisms, and influence on the immune system. They are: dendritic cell therapy, immune checkpoint inhibitors, monoclonal antibodies, and CAR T-cell therapy. Each type is chosen based on the clinical situation and is often incorporated into a personalized treatment plan, especially in cases of advanced or treatment-resistant disease.
Dendritic Cell-Based Immunotherapy for Prostate Cancer
Dendritic cell based immunotherapy for prostate cancer is the most studied and widely applied type of immunotherapy. The discovery of dendritic cells revolutionized cancer treatment and opened new possibilities in strengthening the immune response–an achievement that earned Ralph Steinman the 2011 Nobel Prize in Medicine [3]. A cancer vaccine, based on pre-trained dendritic cells that recognize and attack malignant cells, became the first FDA-approved therapy. Another promising vaccine, LANEX, has shown encouraging results as a progressive and more effective type of prostate cancer immunotherapy. Vaccine for cancer is highly personalized and has a low side effect rate. This makes dendritic cell immunotherapy for prostate cancer treatment a valuable option for those who can’t tolerate the standard approaches.
The LANEX-DC protocol's effectiveness depends on the antigen loading step — training dendritic cells using current tumor-derived antigens, sourced either from tissue biopsy or liquid biopsy. For prostate cancer patients who have received multiple prior treatment lines, the tumor's surface antigen profile at the time of vaccination may differ from its profile at initial diagnosis, because hormone therapy, chemotherapy, and radiation each exert selective pressure on tumor cell populations. A vaccine loaded from outdated or non-representative antigen material is not a personalized vaccine in the clinically meaningful sense.
Booking Health's pre-treatment review assesses whether current biopsy data is available to serve as the antigen source or a liquid biopsy is planned.
CHECK IF A BETTER SOLUTION EXISTS FOR YOUMonoclonal Antibodies for Prostate Cancer
Monoclonal antibodies (bispecific T-cell engager, BiTE). BiTEs are engineered antibodies that bind both T-cells and prostate tumor cells, redirecting immune cells to kill malignant cells without requiring native receptors for tumor antigens [4]. Drugs from this group already have FDA approval for other diseases, and applying them for treating prostate tumors is the next step in clinical research. One key advantage is that such therapy does not require individual synthesis for each patient, reducing the average cost of therapy.
Immune Checkpoint Inhibitors for Prostate Cancer
Immune checkpoint inhibitors (CTLA-4, PD-1/PD-L1) are a complex of immunotherapies for prostate cancer treatment that prevent tumor masking that would normally occur, allowing the human body's immune system to attack the malignant cells. They can be used especially in patients with certain genetic mutations, including the mismatch repair deficiency (dMMR) or the high tumor mutation burden (TMB-H) [5]. Their usage enables application at virtually any level–from the early stages of tumors to advanced disease, recurrence, or even in the instances of metastasis.
CAR T-Cell Therapy for Prostate Cancer
CAR T-cell therapy is a modern immunotherapy for the treatment of prostate cancer that involves genetic modification of a patient’s white blood cells [6]. Extracted leukocytes are engineered to recognize prostate tumors and actively target and eliminate malignant cells. Although highly promising in metastatic disease, this therapy is limited due to high costs and restricted access to gene technologies. But CAR T-cell therapy represents a rapidly evolving frontier in immunotherapy for prostate cancer treatment, with ongoing research aimed at improving safety, scalability, and long-term clinical benefit in advanced and treatment-resistant disease.
Immunotherapy for Early, Advanced, and Metastatic Prostate Cancer
Modern immunotherapy strategies have become an effective therapy against prostate malignancies and have proven to be incredibly efficient in both early-stage and advanced tumors. They may be incorporated into a combined regimen together with surgery, chemotherapy, radiation therapy, and hormone therapy, which gives them more opportunities to treat prostate tumors.
Immunotherapy for Early-Stage Prostate Cancer
Recent studies have proved that immunotherapy not only helps in advanced prostate tumors but also in the early stages. Immunotherapy for stage 2 prostate cancer and stage 1 prostate cancer is mostly administered before or after the surgery. Immunotherapy for early stage prostate cancer, used at the right time, will slow the growth of the tumor. It can also control symptoms and prolong relapse-free survival even at stage 1 prostate cancer treatment. Immunotherapy aims to provide your immune system with a memory of what malignant cells look like to achieve long-lasting immunity.
With increased tolerability, new approaches have become the first-line options for most prostate cancer patients. They are also undergoing research in combination with immune checkpoint inhibitors, and this represents a new frontier in the treatment of prostate tumors in all stages.
Immunotherapy for Advanced Prostate Cancer
The growing list of immunotherapy candidates currently includes not only patients at the early stages, but also men with locally advanced tumors who have had prostate removal but cannot get rid of the malignant cells. Dendritic cell-based vaccines have shown promising results when introduced early, potentially reducing the need for aggressive therapies. In cases when postoperative radiation therapy and chemotherapy are ineffective, and the disease develops resistance to hormones, German medical oncologists turn to immunotherapy for advanced prostate cancer.
Immunotherapy for Metastatic Prostate Cancer
The current immunotherapy for stage 4 prostate cancer is designed to extend the life of men with metastatic disease, to limit tumor cell dissemination, and occasionally to reach a permanent remission, particularly in the earliest stages. Its effectiveness is confirmed by numerous studies and clinical practice. There are schedules of treatments–some types need frequent visits to the hospital, but new ones can be administered more conveniently. As an example, dendritic cell vaccines can be injected in a single session, whereas some checkpoint-based drugs can be administered at home.
Immunotherapy for metastatic prostate cancer in Germany is also used when patients cannot undergo surgery due to contraindication or when other methods of treatment are ineffective, such as recurrence and metastatic disease with resistant prostate tumor cells.
For castration-resistant metastatic prostate cancer specifically — the clinical situation where hormone therapy has failed and the disease has progressed — the immunotherapy selection depends on confirmed PSMA expression, PD-L1 status, and whether dMMR or TMB-H is present.
Each of these molecular features determines which immunotherapy pathway is applicable. A treatment plan for castration-resistant metastatic prostate cancer that is assigned without this molecular characterization is not individualized — it is an approximation.
Booking Health identifies which molecular profiling has been completed and arranges any missing testing in Germany before the treatment protocol is finalized.
Immunotherapy Treatment Process for Prostate Cancer
Monoclonal antibody therapy and immune checkpoint inhibitor therapy need initial laboratory testing. Clinicians are seeking genetic mutations that render malignant cells susceptible to this effective treatment. Doctors also check kidney and liver functioning, the dimensions of the initial tumor in the prostate gland (unless surgery has been conducted), and the existence of metastases, which are located far away. The drugs are mostly administered intravenously after three or four weeks.
The CAR T-cell immunotherapy for prostate cancer is performed in multiple steps. The first step is a thorough examination of the patient and blood tests, with the isolation of leukocytes, which are then genetically altered [7]. It normally takes two or three weeks to make a personalized drug. The procedure is usually carried out in a day hospital. Also, physicians can inject medications to dampen the immunosuppressive environment of the prostate tumors, enabling modified immune cells to more effectively destroy malignant cells.
Vaccination using dendritic cells is based on a two-step program. The initial visit involves clinical and laboratory examinations to prepare the personalized LANEX-DC cancer vaccine. To develop it, specialists can rely on liquid biopsy or tumor tissue fragments. At the second visit, the patient is given the dendritic cell vaccine, in addition to necessary symptomatic treatment. The two stages are performed on an outpatient basis, usually in a single day. This novel approach has demonstrated good outcomes following one injection and can be safely used alongside infusion-based immunotherapy for cancer prostate. Clinical observations confirm that this strategy is not only useful in increasing life expectancy but also in enhancing the immune response against the prostate tumor cells.
In order to grasp the details of this potential treatment, we have interviewed Professor Frank Gansauge, a well-known medical oncologist and expert in the field of dendritic cell-based treatment of prostate tumors, with more than 22 years of experience in this field. His clinic has already recorded impressive breakthroughs in cancer treatment with new immunotherapeutic methods.
VIDEO
Prof. Frank Gansauge: How Dendritic Cell Therapy is Transforming Modern Cancer Treatment
Dendritic Cell Therapy
BOOK CONSULTATION
Combining Immunotherapy with Conventional Prostate Cancer Treatments
The integration of immunotherapy techniques alongside traditional treatments has become standard in modern prostate cancer care. In Germany, doctors carefully assess each patient to tailor the best combination of therapies that enhance immune response, target malignant cells more accurately, and promote long-term disease management. This approach allows patients with early, advanced, or metastatic tumors to access personalized and effective treatment plans that are also safe.
Immunotherapy and Surgery for Prostate Cancer
Surgical intervention is still one of the main methods of managing early prostate tumors and is a part of the treatment of advanced disease. The use of surgical removal of the gland is the main prostate cancer treatment. Immunotherapy, such as dendritic cell vaccines or adoptive cell therapy, strengthens the body's immune system against residual tumor cells.
Immunotherapy, prostate cancer treatment includes, is used before or after the operation to destroy malignancy that might be left behind during surgery, hence lowering the chances of metastatic tumors [9]. The use of prostate-specific antigen provides medical oncologists with an opportunity to monitor for recurrence and adjust treatment options.
Radiation Therapy and Immunotherapy for Prostate Cancer
When combining proton therapy and immunotherapy for prostate cancer, radiation therapy removes existing tumor cells in localized tumors. Immune checkpoint inhibitors and dendritic cell vaccines activate immune cells to identify and destroy malignant cells that have left. This combination is especially helpful in cases of metastatic castration resistant malignancies, whereby traditional radiation treatment might be insufficient to contain tumor growth. In Germany, clinics focus on immunotherapy combining with salvage radiation for prostate cancer. They carefully select dosing and timing to maximize treatment effectiveness, reduce toxicity, and improve patient outcomes.
The timing between radiation and DC vaccination is the variable that determines whether the combination amplifies or undermines the immune response. Radiation-triggered antigen release from destroyed tumor cells creates a window during which dendritic cell vaccination achieves the strongest immune activation — but radiation administered too close to vaccination can damage the circulating immune cells the vaccine depends on
The German clinical team specifies the interval; Booking Health's combination therapy sequencing review confirms that the proposed schedule at the candidate center reflects the timing conditions under which the synergistic effect is actually achieved, not simply that both therapies are offered at the same institution.
FIND THE RIGHT SPECIALIST FOR MY CASEImmunotherapy and Hormone Therapy for Prostate Cancer
Prostate cancer cells can be suppressed by hormone therapy, but when the tumor becomes advanced, it can become resistant to this treatment. Immune checkpoint inhibitors or adoptive cell therapy immunotherapies for prostate cancer treatment are, at this point, reinitiating the immune system to attack hormone-insensitive prostate tumor cells. Clinical observations indicate that when these modalities are combined, they are more effective at killing malignant cells and reducing the risk of disease progression.
Immunotherapy and Chemotherapy for Prostate Cancer
In advanced disease and in cases of metastatic tumors, immunotherapy vs chemotherapy for prostate cancer may be viewed as a shift from primarily cytotoxic tumor reduction to biologically targeted immune modulation. Chemotherapy rapidly controls disease by killing malignant cells systemically, whereas immunotherapy restores long-term immune surveillance, leading to more durable tumor control, especially in biomarker-selected patients.
Vaccines or CAR T-cell therapy help ensure an active immune response that can attack malignant cells during prostate cancer treatment. Immunotherapy for prostate cancer management combined with chemo enables medical oncologists to optimize treatment options while managing the growth of the tumor and enhancing the quality of life of patients.
Personalized Combination Treatment Planning for Prostate Cancer
The need to combine immunotherapy for prostate cancer treatment with conventional approaches must be closely monitored. Imaging, molecular tests, and prostate-specific antigen levels provide medical oncologists with guidance for modifying therapy. Individualized plans can be used to ensure that immune checkpoint inhibitors, adoptive cell therapy, or other immunotherapy drugs are applied to supplement surgery, radiation, and chemotherapy without compromising patient safety. This strategy is used when receiving immunotherapy treatment for prostate cancer in Germany. It is not only highly effective against malignant cells but also provides a guideline for treating tumors at all stages, including early-stage and metastatic castration-resistant prostate disease.
Comparing the Effectiveness of Prostate Cancer Treatment Methods
The immunotherapy effectiveness for prostate cancer patients depends on clinical factors, tumor genetics, and disease stage. In modern oncology, the comparison of immunotherapy vs chemotherapy for prostate cancer reflects a broader shift toward personalized treatment selection rather than a one-size-fits-all approach.
Chemotherapy can provide tumor control, but its effects are limited by systemic toxicity and the development of resistance. Another option, such as targeted therapy or hormonal therapy, can only be effective in certain tumor types and cannot be routinely used for every patient.
On the other hand, immunotherapeutic approaches like dendritic cell vaccination are more selective but offer the potential for longer-lasting disease control by activating the patient’s immune system. This makes immunotherapy particularly valuable in scenarios where long-term disease stabilization is the goal, especially after progression on hormone therapy or chemotherapy. It is also increasingly considered in combination strategies to enhance overall treatment response.
Take a closer look at the comparison table of different prostate tumor treatment strategies.
Comparison of Prostate Cancer Treatments
| Therapy type | Toxicity | Therapy Duration | Early Stage Effectiveness (5-year survival rate) | Duration of treatment effect |
|---|---|---|---|---|
| Chemotherapy | High (65-80%) | Depending on the stage, lifelong | up to 75%, with significant side effects | Short-term effect, limited to the course of treatment |
| Hormone therapy | Low (10-15%) | Given for several months, usually followed by chemotherapy | up to 70% for hormone-sensitive cases only | The effect is present only during treatment |
| Dendritic cell vaccines | Very low (about 1%) | Single injection and lifelong immunity | up to 95% with minimal impact on quality of life | Reliable long-term result, long-lasting remission |
| Targeted therapy | Low (15-20%) | Depending on the stage, treatment may take about a year | up to 75% for matching mutations only | The effect is quite long-lasting in the presence of specific mutations in the tumor |
Benefits of Immunotherapy for Prostate Cancer
Designed to treat advanced prostate cancer, immunotherapy has since become effective in virtually all stages–from early-stage prostate tumors to metastatic castration resistant prostate disease.
It has the following advantages:
- Effective in work irrespective of the sensitivity of prostate tumor cells to hormones
- Treats initial lesions in the prostate gland and metastasis
- Removes the disease even in cases where the normal chemotherapy is unable to kill malignant cells
- Extends life span and quality of life
- Combinations with other treatment modalities like surgery, hormone therapy, or radiation have good results
With such advantages, immunotherapy and prostate cancer personalized vaccines have emerged as one of the most promising and efficient treatment approaches for patients, particularly those with metastatic or resistant tumors.
Choosing Clinics for Prostate Cancer Immunotherapy in Germany
When choosing among the prostate cancer immunotherapy clinics, there are a few key features to consider:
- The presence of multidisciplinary tumor boards aims to create a personalized treatment plan.
- Access to modern molecular diagnostics and biomarker testing, which play a central role in determining eligibility for prostate cancer immunotherapy in Germany.
- Extensive experience in managing patients with an immunotherapeutic approach.
- The availability of multimodal treatment options, which combine immunotherapy with hormone therapy, chemotherapy, or radiation, improves treatment effectiveness.
- Comprehensive support for international patients.
This ensures that you will receive the best care when undergoing treatment like prostate cancer immunotherapy clinics in Germany.
The molecular diagnostics criterion above is the most consequential of the five — because a center that offers DC vaccination, checkpoint inhibitors, and CAR T-cell therapy without the in-house capacity to confirm PSMA expression, dMMR status, PD-L1 characterization, and TMB cannot reliably assign which of those therapies applies to a specific patient.
The therapy menu and the diagnostic infrastructure that makes it personalized are different things, and not all centers that list immunotherapy among their offerings have both.
Booking Health's center matching for prostate cancer immunotherapy evaluates each center's documented molecular profiling capability alongside its immunotherapy caseload.
GET A SECOND OPINION FOR MY CASEWhy Germany Is a Leading Destination for Prostate Cancer Immunotherapy
Germany is known globally for having advanced oncology care. In Germany, medical facilities have the latest diagnostic equipment, such as molecular profiling, prostate-specific antigen test, and high-end imaging, which enables access to the most innovative immunotherapy for prostate cancer.
The main benefits of receiving prostate cancer immunotherapy in Germany include:
- Individualized treatment programs:German medical oncologists develop individualized plans and select the most effective immunotherapy based on the disease stage, the patient's genetic features, and the patient's health status.
- Combination:Immunotherapy can be combined with surgery, radiation, hormone therapy, or chemotherapy in order to enhance the treatment effect and maximize the survival in metastatic or advanced disease.
- Safety and high level of oversight:The immune response and potential side effects are continuously monitored, ensuring that patients can tolerate treatment.
- Comprehensive patient care:Germany focuses on the patient-centered approach and improving quality of life, as well as patient education about the appropriate treatment.
Cost of Immunotherapy for Prostate Cancer in Germany
The cost of immunotherapy for prostate cancer varies significantly depending on the chosen country. For example, in the United States, prostate cancer immunotherapy is typically the highest, due to high healthcare expenses and limited access to advanced healthcare facilities for patients. In Great Britain, access to certain therapies may be limited in the public system, leading to delays or requiring private treatment. In contrast, immunotherapy treatment for prostate cancer in Germany is often more affordable, with high therapy quality.
To compare the prostate cancer immunotherapy cost in Germany and other countries, take a look at the table below.
Cost of Immunotherapy for Prostate Cancer Treatment in Different Countries
| Country | Dendritic cell therapy price | CAR T-cell therapy price | Checkpoint inhibitors price |
|---|---|---|---|
| Germany | €20,000 - €38,000 | €450,000 - €550,000 | €20,000 - €40,000 for 1 cycle |
| USA | €100,000 - €150,000 | $500,000 - $750,000 | €50,000 - €60,000 for 1 cycle |
| Great Britain | Not available | Not available | €90,000 - €100,000 for 1 cycle |
| Australia | Not available | Not available | Not available |
The DC therapy gap between Germany and the US — up to €130,000 — is the starkest figure in this table for patients from countries where the therapy is unavailable entirely. For British and Australian patients, the financial comparison is irrelevant: Germany is the only access point.
Booking Health patients access Germany's treatment costs without the foreign patient surcharge that clinics apply to self-referred people. You receive a fully itemized budget and complication insurance of €200,000, and unspent funds are returned after the program concludes.
Get full treatment coordination supportTreatment Planning and Medical Support with Booking Health
When looking for prostate cancer immunotherapy clinics in Germany, it may seem challenging at first. When you receive opinions from multiple specialists and have tried various therapeutic interventions, you may feel overwhelmed by all the information from the doctors. It is important to avoid rushing into first-line options or adhering strictly to standardized therapeutic protocols that have many adverse effects, instead opting for highly specialized, innovative treatments like immunotherapy for prostatic cancer.
This is where Booking Health can make a difference. With over 12 years of experience arranging medical treatment abroad for patients from around the world, we work to provide you with a personalized prostate cancer management plan tailored to your specific clinical situation. Booking Health can organize prostate cancer immunotherapy in Germany with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment.
We provide:
- Careful analysis and assessment of your medical documentation
- Clinic selection
- Development of a personalized medical program
- Forwarding all the necessary documentation to the appropriate clinic
- Consultations with leading specialists in the field
- Help with all the medical preparation before the start of the treatment
- Assistance with visa and tickets
- Coordination and organization of the patient's stay in a foreign country
- Personal coordinator and interpreter available 24/7
- Transparent budgeting with no hidden costs
Booking Health ensures that every patient gets the most up-to-date management of their disease. They only work with experts with proven experience and a reputation. With us, you will be able to pursue stronger health and a better quality of life even when dealing with a diagnosis like prostate cancer. Contact our team to learn more about the possibilities for personalized treatment with immunotherapy and to connect with leading specialists in this field.
Booking Health holds ISO 9001 quality certification, reflecting well-established processes and strict quality control at every stage of the treatment journey — not just at the initial consultation, but throughout.
Modern Cancer Treatment: Patient Journeys with Booking Health
FAQ: Immunotherapy for Prostate Cancer
Prostate cancer as a model for tumour immunotherapy is an important concept in oncology. It represents a growing field of therapies that stimulate the patient's own immune system to target malignant cells. It includes therapeutic cancer vaccines, immune checkpoint inhibitors, and cell-based therapies.
Prostate cancer immunotherapy drugs work by inducing the immune system of an individual to identify and destroy malignant cells. It is a treatment aimed at certain proteins or receptors of the cancer cells.
Yes, it can be used particularly in advanced and metastatic cases, or if the tumor is resistant to other treatments. It is also often combined with other therapies to increase the effectiveness.
Immunotherapy is a specific form of treatment, and it has fewer side effects than the usual treatments, and it may lead to permanent remission. It offers a new hope to patients with advanced or resistant prostate tumors.
The effectiveness depends on the tumor’s unique characteristics. If used as a personalized treatment plan, many patients can benefit from improved disease control and immune-mediated tumor suppression.
The immunotherapy effectiveness for prostate cancer is monitored through regular imaging tests, blood tests, and clinical evaluations. These tests assist physicians in assessing the effectiveness of the therapy and making any necessary modifications.
The immunotherapy success rate for prostate cancer varies depending on the type of therapy. For example, the success rate for dendritic cell therapy can reach up to 95%.
Immunotherapy for prostate cancer side effects are fatigue, skin reactions, and flu-like symptoms. Severe side effects of immunotherapy for prostate cancer are infrequent, yet may happen and have to be closely monitored during treatment.
Yes, immunotherapy may be used in combination with standard therapies, such as surgery, chemotherapy, radiation therapy, and targeted therapy. A combination of treatments will increase the overall effect and will be more effective and beneficial to patients.
Yes, it is available across Europe, particularly in Germany, which has the most specialized oncological centers. They also integrate immunotherapy into a comprehensive treatment strategy, allowing for the best outcomes possible.
Patients can access immunotherapy in different treatment centers abroad, but it is most developed in Germany. The centers there offer multidisciplinary treatment planning and integration of immunotherapy with other modalities such as hormone therapy and radiation.
Germany has high technologies and oncologists with a high level of experience, as recognized by the German Cancer Society. A tumor board with multidisciplinary review is applied to every case.
Laboratories Dr. Gansauge in Berg, IOZK Immuno-Oncology Center in Cologne, and Praxisgemeinschaft für Zelltherapie in Duderstadt are the most famous clinics that offer immunotherapy for patients with prostate tumors.
There are different treatment costs一dendritic cell vaccines €20 000 - €38,000, monoclonal antibody treatment €375 000 - €420 000, and CAR T-cell therapy €450,000 - €550,000. The cost will largely depend on the program and a combination of therapies.
The toxicity of dendritic cell vaccines is about 1%–this is the safest option. Hormone therapy shows moderate toxicity of 10-15%, and targeted therapy shows 15-20% toxicity. Chemotherapy impacts quality of life the most.
Yes, successful immunotherapy for stage IV prostate cancer can provide long-term disease control and slowed progression when combined with other treatments, especially in castration-resistant cases.
Treatment duration varies considerably depending on the approach selected. Dendritic cell vaccines require only a single injection that creates lifelong immunity, representing the most convenient option. Hormone therapy is given for several months before transitioning to other treatments, while targeted therapy may continue for about a year, depending on stage. Chemotherapy duration extends up to lifelong administration in some cases.
With vaccines using dendritic cells, patients can achieve up to 95% 5-year survival. Chemo- and targeted therapy can offer up to 75%. Hormone therapy is quite effective, up to 70%, but it works only in hormone-sensitive cases.
Vaccination with dendritic cells provides long-term results–lifelong anticancer immunity is a reality after just a single injection. Hormone therapy and chemotherapy effects are significant only during active treatment. Targeted therapy demonstrates long-lasting effects, but its administration is limited to the presence of specific mutations.
In Germany, a patient pays €20,000-€38,000 for dendritic cell vaccines and €10,000-€15,000 for hormone therapy. Targeted therapy costs €375,000 - €420,000 for the full course, and the chemotherapy full course is about €80,000 - €150,000.
In Germany, patients can access advanced immunotherapy programs. Treatments are individualized and administered in specialized centers. Also, they are combined with standard oncology care to enhance immune response.
Germany has one of the most effective immunotherapies for prostate cancer–dendritic cell vaccines, CAR T-cell therapy, and active immunotherapy vaccines. They are also available to patients in dedicated cancer facilities, where patients can get high-quality care and specific programs tailored to each stage of the disease.
Booking Health support with immunotherapy in Germany assists international patients with the organization of appointments, choosing the most successful clinics, and organizing transportation and treatment. The BH team takes patients through the process of medical paperwork, insurance, and follow-up after treatment, so they can access groundbreaking immunotherapy to treat prostate cancer in Germany.
Choose treatment abroad and you will for sure get the best results!
Sources:
01. Oskar Bergengren, Kelly R Pekala, Konstantina Matsoukas et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. Eur Urol. 2023 May 16;84(2):191–206. doi: 10.1016/j.eururo.2023.04.021. [DOI] [PMC free article]
02. Ian Wang, Liankun Song, Beverly Y Wang et al. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022 Aug 15;10(4):210–233. [PMC free article]
03. Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
04. Harriet Lampe, Laura Tam, Aaron R Hansen. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future. Front Pharmacol. 2024 May 30;15:1399802. doi: 10.3389/fphar.2024.1399802. [DOI] [PMC free article]
05. Shobi Venkatachalam, Taylor R McFarland, Neeraj Agarwal, Umang Swami. Immune Checkpoint Inhibitors in Prostate Cancer. Cancers (Basel). 2021 May 2;13(9):2187. doi: 10.3390/cancers13092187. [DOI] [PMC free article]
06. Mahmood S Choudhery, Taqdees Arif, Ruhma Mahmood, David T Harris. CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects. J Clin Med. 2024 May 29;13(11):3202. doi: 10.3390/jcm13113202. [DOI] [PMC free article]
07. Zugasti, I., Espinosa-Aroca, L., Fidyt, K. et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther 10, 210 (2025). https://doi.org/10.1038/s41392-025-02269-w. [DOI]
08. Dhivya Sridaran, Elliot Bradshaw, Carl DeSelm et al. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023 Sep 21;4(10):101199. doi: 10.1016/j.xcrm.2023.101199. [DOI] [PMC free article]
09. Lu H, Teng Z, Wang J, and Zhang W (2025). Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors. Front. Immunol. 16:1583363. doi: 10.3389/fimmu. 2025.1583363. [DOI]
10. Jide He, Jialong Wu, Ziang Li et al. Immunotherapy Vaccines for Prostate Cancer Treatment. Cancer Med. 2024 Oct 28;13(20):e70294. doi: 10.1002/cam4.70294. [DOI] [PMC free article]
Read:
